Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, Stejskal L, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, Hájek R.

Cancer Med. 2018 Aug;7(8):4132-4145. doi: 10.1002/cam4.1620. Epub 2018 Jun 21.

2.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A.

Biol Blood Marrow Transplant. 2018 Aug 22. pii: S1083-8791(18)30478-6. doi: 10.1016/j.bbmt.2018.08.013. [Epub ahead of print]

PMID:
30142419
3.

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.

González-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R.

Ann Hematol. 2018 Aug;97(8):1453-1462. doi: 10.1007/s00277-018-3316-7. Epub 2018 Apr 6.

PMID:
29623394
4.

Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.

Brozova L, Jarkovský J, Pour L, Minárik J, Jungová A, Gregora E, Spicka I, Maisnar V, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):51-59. doi: doi: 10.14735/amko20172S51.

PMID:
28903571
5.

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.

Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):e219-e240. doi: 10.1016/j.clml.2018.04.003. Epub 2018 Apr 17.

PMID:
29793653
6.
7.

[Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].

Lu J, Du J, Fu WJ, He HY, Li L, Li R, Zhou LL, Jiang H, Hou J.

Zhonghua Xue Ye Xue Za Zhi. 2017 Jun 14;38(6):475-479. doi: 10.3760/cma.j.issn.0253-2727.2017.06.003. Chinese.

PMID:
28655089
8.

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P.

J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.

9.

[Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) -  Benefit for Stratification of Multiple Myeloma?].

Ščudla V, Lochaman P, Pika T, Zapletalová J, Minařík J, Bačovský J.

Klin Onkol. 2015;28(5):359-69. Czech.

PMID:
26480864
10.

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K.

Hematol Oncol. 2018 Sep 3. doi: 10.1002/hon.2559. [Epub ahead of print]

PMID:
30176173
11.

Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.

Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, Lee JH, Park Y, Lee HS, Eom HS, Shin HJ, Min CK, Kim JS, Jo JC, Kang HJ, Mun YC, Lee WS, Lee JJ, Suh C, Kim K; and the Korean Multiple Myeloma Working Party.

Am J Hematol. 2017 Dec;92(12):1280-1286. doi: 10.1002/ajh.24891. Epub 2017 Sep 8.

PMID:
28833417
12.

Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.

Dutoit JC, Vanderkerken MA, Verstraete KL.

Eur J Radiol. 2013 Sep;82(9):1444-52. doi: 10.1016/j.ejrad.2013.04.012. Epub 2013 May 28.

PMID:
23726124
13.

Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma.

Zhuang J, Da Y, Li H, Han B, Wan X, Zhu T, Chen M, Duan M, Xu Y, Zhao Y, Shen T, Wua Y, Zhou D.

Leuk Res. 2014 Feb;38(2):188-93. doi: 10.1016/j.leukres.2013.11.010. Epub 2013 Nov 19.

PMID:
24342807
14.

Revised International Staging System Applied to Real World Multiple Myeloma Patients.

Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.

PMID:
27425179
15.

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.

Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas D, Panagiotidis I, Kafantari E, Giannouli S, Zomas A, Konstantopoulos K, Dimopoulos MA.

Haematologica. 2017 Mar;102(3):593-599. doi: 10.3324/haematol.2016.145078. Epub 2016 Oct 27.

16.

Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.

Brozova L, Schwarz D, Snabl I, Kalina J, Pavlickova B, Komenda M, Jarkovský J, Němec P, Horinek D, Stefanikova Z, Pour L, Hájek R, Maisnar V.

Klin Onkol. 2017 Summer;30(Supplementum2):43-50. doi: 10.14735/amko20172S43.

PMID:
28903570
17.

Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma.

Gupta R, Kaur G, Kumar L, Rani L, Mathur N, Sharma A, Dahiya M, Shekhar V, Khan S, Mookerjee A, Sharma OD.

Ann Hematol. 2018 Dec;97(12):2447-2454. doi: 10.1007/s00277-018-3457-8. Epub 2018 Jul 28.

PMID:
30056581
18.

[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].

Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):217-21. Chinese.

PMID:
18843972
19.

Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.

Scudla V, Lochman P, Pika T, Minarik J, Zapletalova J, Bacovsky J.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):84-93. doi: 10.5507/bp.2015.032. Epub 2015 Aug 4.

20.

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group.

Leukemia. 2013 Mar;27(3):711-7. doi: 10.1038/leu.2012.282. Epub 2012 Oct 3.

Supplemental Content

Support Center